A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

Inclusion Criteria:

• Male or female aged >=18 to <= 80 years, or minimum age of adult consent according tolocal regulations, at the Baseline Visit. Where locally permissible, participants 16to < 18 years of age who meet the definition of Tanner stage 5 for development at theBaseline Visit.
• Diagnosis of CD for at least 3 months prior to Baseline.
• Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF),abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD).
• Demonstrated intolerance or inadequate response to conventional or to biologic therapyfor CD.
• If female, participant must meet the contraception recommendations.

Exclusion Criteria:

• Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.
• Participants with unstable doses of concomitant Crohn's disease therapy.
• Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab,certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumabwithin 12 weeks prior to Baseline), or any investigational biologic or other agent orprocedure within 35 days or 5 half-lives prior to Baseline, whichever is longer.
• Prior exposure to p19 inhibitors (e.g., risankizumab).
• Complications of Crohn's disease.
• Having an ostomy or ileoanal pouch.
• Known active Coronavirus Disease 2019 (COVID-19) infection.